Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Immunol., 08 October 2025

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1708889

This article is part of the Research TopicCommunity Series in Reducing Adverse Effects of Cancer Immunotherapy: Volume IIIView all 14 articles

Correction: Real-world outcomes of immune checkpoint inhibitors as second-line therapy for extensive-stage small-cell lung cancer: a multicenter retrospective analysis

This article is a correction to:

  1. Real-world outcomes of immune checkpoint inhibitors as second-line therapy for extensive-stage small-cell lung cancer: a multicenter retrospective analysis

    1. Read original article
Jiao Zhang,&#x;Jiao Zhang1,2†Jia-xing Guo&#x;Jia-xing Guo3†Ping LiPing Li4Xiao-ye JinXiao-ye Jin5Yan Wang*Yan Wang1*Lu-jun Zhao*Lu-jun Zhao2*
  • 1The Third Department of Medical Oncology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China
  • 2Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China
  • 3Department of Radiation Oncology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region, China
  • 4Department of Pharmacy, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China
  • 5College of Clinical Medical, Ningxia Medical University, Yinchuan, Ningxia, China

A Correction on
Real-world outcomes of immune checkpoint inhibitors as second-line therapy for extensive-stage small-cell lung cancer: a multicenter retrospective analysis

By Zhang J, Guo J-x, Li P, Jin X-y, Wang Y and Zhao L-j (2025). Front. Immunol. 16:1658017. doi: 10.3389/fimmu.2025.1658017

In the Abstract, In the Results section of the Abstract: Line 4: The values “4.14 vs. 2.84” are incorrect. Line 5: The values “4.21 vs. 2.87” are incorrect. This has been corrected to read:

Line 4: The original data has been changed to “4.13 vs. 2.70”. Line 5: The original data has been changed to “4.14 vs. 2.84”.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: extensive-stage small cell lung cancer, immune checkpoint inhibitors, second-line therapy, survival, prognosis

Citation: Zhang J, Guo J-x, Li P, Jin X-y, Wang Y and Zhao L-j (2025) Correction: Real-world outcomes of immune checkpoint inhibitors as second-line therapy for extensive-stage small-cell lung cancer: a multicenter retrospective analysis. Front. Immunol. 16:1708889. doi: 10.3389/fimmu.2025.1708889

Received: 19 September 2025; Accepted: 03 October 2025;
Published: 08 October 2025.

Edited and reviewed by:

Cleber Machado-Souza, Pelé Pequeno Príncipe Research Institute, Brazil

Copyright © 2025 Zhang, Guo, Li, Jin, Wang and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Lu-jun Zhao, emhhb2x1anVuQHRqbXVjaC5jb20=; Yan Wang, bWd3eTE5NzRAMTYzLmNvbQ==

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.